Unicycive Therapeutics (UNCY) Net Income (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Net Income came in at -$19.9 million in Q1 2026, down 153.15% YoY from $37.5 million in Q1 2025, and down 208.89% on a QoQ basis from -$6.4 million in Q4 2025.
Unicycive Therapeutics (UNCY) Net Income (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of Net Income data on file, last reported at -$19.9 million in Q1 2026.
- Quarterly Net Income fell 153.15% year-over-year to -$19.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$53.1 million (down 70.82% YoY) and the FY2025 annual result came in at -$54.2 million, down 7.22% from the prior year.
- Net Income fell to -$19.9 million in Q1 2026, from -$6.4 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$3.8 million in Q1 2022 to a low of -$233.3 million in Q1 2023.
- A 5-year average of -$29.4 million and a median of -$7.9 million in 2025 frame the typical range for Net Income.
- Annual changes were most pronounced in 2023 — Net Income tumbled 6028.67% — and 2024, when it jumped 96.04%.
- Tracing UNCY's Net Income over 5 years: stood at -$5.3 million in 2022, then declined by 16.22% to -$6.2 million in 2023, then slumped by 43.86% to -$8.9 million in 2024, then climbed by 27.66% to -$6.4 million in 2025, then slumped by 208.89% to -$19.9 million in 2026.
- The last three Net Income figures came in at -$19.9 million (Q1 2026), -$6.4 million (Q4 2025), and -$14.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | -9.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.60 Mn |
| Mar 31, 2026 | -19.91 Mn |
| Dec 31, 2025 | -6.44 Mn |
| Sep 30, 2025 | -14.57 Mn |
| Jun 30, 2025 | -12.22 Mn |
| Mar 31, 2025 | -7.86 Mn |
| Dec 31, 2024 | -8.91 Mn |
| Sep 30, 2024 | -6.71 Mn |
| Jun 30, 2024 | -7.63 Mn |
| Mar 31, 2024 | -9.24 Mn |
| Dec 31, 2023 | -6.19 Mn |
| Sep 30, 2023 | -40.97 Mn |
| Jun 30, 2023 | -106.95 Mn |
| Mar 31, 2023 | -233.26 Mn |
| Dec 31, 2022 | -5.33 Mn |
| Sep 30, 2022 | -5.75 Mn |
| Jun 30, 2022 | -3.87 Mn |
| Mar 31, 2022 | -3.81 Mn |
| Dec 31, 2021 | -2.56 Mn |
| Sep 30, 2021 | -4.77 Mn |